Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Jul 22, 2024, 21.16PM ISTInheriting bone most cancers generally is a main concern. This video explores the elements influencing bone most cancers and...
A latest research printed in In Vivo evaluated the efficacy of varied monotherapies and mixture therapies on T-cell acute lymphoblastic leukemia (T-ALL) cell...
